CNCE · Concert Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $32.58M | $7.90M | $1.08M | $174.0K | $143.89M | $174.0K |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $87.56M | $61.62M | $59.82M | $43.15M | $30.22M | $36.98M |
| SG&A | $22.53M | $18.93M | $20.28M | $22.94M | $21.02M | $14.36M |
| Total Operating Expenses | $110.09M | $80.55M | $80.09M | $66.09M | $51.24M | $51.34M |
| D&A | $1.48M | $1.60M | $1.66M | $1.25M | $1.01M | $893.0K |
| Operating Income | ($77.51M) | ($72.65M) | ($79.02M) | ($55.58M) | $92.65M | ($51.17M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $0 | ($85.0K) | $0 | $313.0K | ($300.0K) | $0 |
| Net Income | ($80.05M) | ($74.77M) | ($78.17M) | ($56.02M) | $95.64M | ($50.72M) |
| EPS - Basic | ($2.40) | - | - | ($2.40) | $4.20 | ($2.28) |
| EPS - Diluted | ($2.40) | - | - | ($2.40) | $4.06 | ($2.28) |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $141.64M | $77.20M | $53.04M | $17.77M | $27.66M | $40.55M |
| Accounts Receivable | $218.0K | $686.0K | $72.0K | $15.0K | $155.0K | $27.0K |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.61M | $230.0K | $881.0K | $1.28M | $658.0K | $545.0K |
| Current Assets | $150.33M | $142.72M | $116.86M | $180.15M | $205.73M | $97.73M |
| Total Assets | $165.32M | $159.26M | $137.47M | $192.55M | $211.74M | $100.39M |
| Current Liabilities | $16.12M | $10.18M | $17.27M | $8.75M | $6.45M | $5.57M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $53.09M | $28.10M | $36.01M | $24.81M | $15.30M | $14.80M |
| Stockholders' Equity | $112.22M | $131.16M | $101.46M | $167.74M | $196.43M | $85.59M |
| Retained Earnings | ($349.50M) | ($269.45M) | ($116.52M) | ($116.52M) | ($76.24M) | ($171.88M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($55.15M) | ($69.04M) | ($48.76M) | ($45.34M) | $102.93M | ($45.34M) |
| Investing Cash Flow | $52.46M | $344.0K | $82.58M | ($7.21M) | ($121.31M) | ($7.21M) |
| Financing Cash Flow | $67.13M | $92.85M | $1.45M | $601.0K | $5.49M | $601.0K |
| CapEx | $255.0K | $210.0K | $685.0K | $2.87M | $947.0K | $770.0K |
| Free Cash Flow | ($55.41M) | ($69.25M) | ($49.45M) | ($48.21M) | $101.98M | ($46.11M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -237.9% | -919.3% | -7336.6% | -31944.8% | 64.4% | -29406.3% |
| EBITDA margin | -233.4% | -899.0% | -7182.1% | -31228.2% | 65.1% | -28893.1% |
| Net margin | -245.7% | -946.2% | -7257.8% | -32197.7% | 66.5% | -29149.4% |
| Free cash flow margin | -170.1% | -876.3% | -4591.1% | -27708.0% | 70.9% | -26501.7% |
| FCF / Net income | 0.69 | 0.93 | 0.63 | 0.86 | 1.07 | 0.91 |
| R&D / Revenue | 268.8% | 779.9% | 5553.9% | 24798.3% | 21.0% | 21254.6% |
| SG&A / Revenue | 69.2% | 239.5% | 1882.6% | 13183.9% | 14.6% | 8251.7% |
| Effective tax rate | - | - | - | - | -0.3% | - |
| Return on assets | -48.4% | -46.9% | -56.9% | -29.1% | 45.2% | -50.5% |
| Return on equity | -71.3% | -57.0% | -77.0% | -33.4% | 48.7% | -59.3% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 9.33 | 14.02 | 6.77 | 20.59 | 31.92 | 17.55 |
| Quick ratio | 9.33 | 14.02 | 6.77 | 20.59 | 31.92 | 17.55 |
| Cash ratio | 8.79 | 7.59 | 3.07 | 2.03 | 4.29 | 7.28 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.47 | 1.21 | 1.35 | 1.15 | 1.08 | 1.17 |
| Liabilities / Assets | 0.32 | 0.18 | 0.26 | 0.13 | 0.07 | 0.15 |
| Efficiency | ||||||
| Asset turnover | 0.20 | 0.05 | 0.01 | 0.00 | 0.68 | 0.00 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 2d | 32d | 24d | 31d | 0d | 57d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 312.3% | 633.7% | 519.0% | -99.9% | 82596.0% | -99.7% |
| Revenue CAGR (3y) | 472.1% | -62.0% | 83.6% | -86.2% | 123.7% | - |
| Revenue CAGR (5y) | 184.8% | -34.7% | -39.1% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -6.7% | 8.1% | -42.2% | - | - | - |
| Net income growth (YoY) | -7.1% | 4.3% | -39.5% | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | 54.3% |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 20.0% | -40.0% | -2.6% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -14.4% | 29.3% | -39.5% | -14.6% | 129.5% | -34.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$32.58M totalOther Revenue$32.54M · 99.9%
License And Research And Development Revenue$39.0K · 0.1%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-1.58
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CONCERT PHARMACEUTICALS against the 5 most active filers in the same SIC group.